Dramatic response to cyclin D-dependent kinase 4/6 inhibitor in refractory poorly differentiated neuroendocrine carcinoma of the breast.
We present a patient with high-grade neuroendocrine carcinoma of the breast who had a successful and durable response to the cyclin D-dependent kinase (CDK) 4/6 inhibitor palbociclib in conjunction with endocrine therapy. This patient was refractory to commonly used platinum-based chemotherapy as well as hormone-based treatment. To date, this is the first published case of use of CDK 4/6 inhibitor in primary neuroendocrine carcinoma of the breast.
PMID: 29904310 [PubMed]
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Shanks A, Choi J, Karur V Tags: Proc (Bayl Univ Med Cent) Source Type: research
More News: Brain | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Endocrine Therapy | Gastroenterology | Hormones | Neurology